New Jersey Assembly Bill A2254

New Jersey 2022-2023 Regular Session

• Introduced: 2/7/22
• Refer: 2/7/22

Caption

Requires Medicaid preferred drug lists to provide for coverage of buprenorphine for treatment of chronic pain.

Impact

If enacted, A2254 would significantly alter the landscape of medication accessibility within New Jersey's Medicaid program. By ensuring that buprenorphine is available for individuals suffering from chronic pain without supplementary requirements, the bill seeks to enhance healthcare access for patients who might otherwise face delays in receiving appropriate treatment. Furthermore, it directs the Commissioner of Human Services to pursue state plan amendments or waivers needed for federal financial participation, emphasizing the collaborative nature of state and federal health initiatives.

Summary

Assembly Bill A2254, introduced in February 2022, mandates that Medicaid preferred drug lists include coverage for buprenorphine specifically for the treatment of chronic pain. The bill underscores the necessity of this medication being prescribed by licensed medical practitioners without the imposition of any step therapy requirements, which often necessitate patients to try other medications before accessing the desired treatment.

Contention

The introduction of A2254 might generate discussions surrounding the implications of reduced restrictions on prescription practices within the Medicaid framework. Supporters of the bill may argue that it provides much-needed relief for chronic pain sufferers, while opponents could raise concerns about the risks associated with increased availability of opioid medications. This could lead to debates on balancing proper control measures with patient needs in medication prescribing, especially in the context of ongoing discussions regarding opioid addiction and management.